Explore
Premium
Sign Up
Log In
The Role of Long-Term DAPT after STEMI - David Cohen
↳ This is a section part of Moment:
CRT 2017 : Optimization of Anticoagulation for STEMI Therapy - Supported by educational grants from AstraZenca, Chiesi USA, Inc. and Medicure, Inc.
Add this Moment to your Passport
Learn from this moment and keep it forever.
Add To Passport
$16.99
This moment is included in Simple Premium - Get started for free.
FREE
with Simple Premium
Start your 30-day free trial
Simple Premium offers unlimited access to all premium moments.
$30.00 per month. Cancel anytime.
Preview
Summary
The Role of Long-Term DAPT after STEMI - David Cohen at CRT 2017.
Add this Moment to your Passport
Learn from this moment and keep it forever.
Add To Passport
$16.99
This moment is included in Simple Premium - Get started for free.
FREE
with Simple Premium
Start your 30-day free trial
Simple Premium offers unlimited access to all premium moments.
$30.00 per month. Cancel anytime.
Target Audience
Learning Objectives
Other Components in this Moment
Overview
Case Presentation - Kyle Buchanan
Is There Such a Thing as Adequate P2Y12 Pretreatment for ACS?: Contemporary Use of IV Antiplatelet Agents - Paul Gurbel
Maintaining Ischemic Protection While Improving Safety Outcomes: Can We Standardize Short Infusion Glycoprotein IIb/IIIa Inhibitor Use? - Michael Lipinski
Antiplatelet Options in the Cathlab: How Can We Find Value? - Michael Lipinski
Case Presentation - M Chadi Alraies
Should We Preload STEMI Patients With Antiplatelet Therapy? - A. Michael Lincoff
Antiplatelet Therapy for STEMI: The Case for Cangrelor - Gary Schaer
The Role of Long-Term DAPT after STEMI - David Cohen
Loading Simple Education
